Background: Mesothelioma is a disease that attacks the mesothelium cells or the external part of the organ. Mesothelioma often attacks pleura of the lung organs. One of the development of mesothelioma is Benign Papillary Mesothelioma. This disease is a rare disease. Benign Papillary Mesothelioma is a cancer that caused by the Simian-40 virus (SV-40) and can be induced by exposure to asbestos. Purpose: This study aimed to record the pathogenesa of Benign Papillary Mesothelioma disease in a female patient. Methods: This study used the recording data of patient from the clinical data, radiological and histopathological as the supporting data. In patient’s history, the patient's condition experienced progression by a pleural effusion, SVKS and a high risk of thrombosis. That invasion was examined by the results of pleural fluid analysis, pleural fluid cytology and chest X-ray CT with contrast. Result: In patients with tumors, an emergency could occur if it did not treated immediately and caused a life threatening. The drugs management of patients with SVKS and the risk of thrombosis can help reduce patient complaints. Conclusions: Mass biopsy was also conducted by using HE staining, where the diagnosis results told the patient has chronic pleurisy, pulmonary edema and congestion. Patients were planned for platinum-based chemotherapy.

• Ames PRJ, Aye WW. Case Report Pleural mesothelioma and venous thrombosis: the eosinophilia link. Thrombosis Journal 2008; 6(3) : 1-3
• Attanoos RL, Webb R, Dojcinov SD, Gibbs AR. Value of mesothelial and epithelial antibodies in distinguishing diffuse peritoneal mesothelioma in females from serous papillary carcinoma of the ovary and peritoneum Histopathology 2002;40:237–244.
• Bicer M, Yaldız S, Gursoy S, Ulgan M. A case of giant benign localized fibrous tumor of the pleura. European Journal of Cardio-thoracic Surgery 1998; 14 : 211–213
• Brimo F Et all. Mesothelioma of the tunica vaginalis: a series of eight cases with uncertain malignant potential. Modern Pathology. 2010; 23 : 1165–1172
• Bürrig KF, Pfitzer P, Hort W. Well-differentiated papillary mesothelioma of the peritoneum: a borderline mesothelioma. Report of two cases and review of literature. Virchows Arch A Pathol Anat Histopathol. 1990 ; 417: 443–7
• Cancer Research UK Mesothelioma risk and causes. Cancer help.org.uk. 2010-06-23. Retrieved 2010-08-20
• Chen S.E, Pace M B. Malignant Pleural Mesothelioma. American Journal of Health-System Pharmacy. 2012 ; 69 (5) : 377 – 385
• Elmes PC, Simpson JMC: The clinical aspects of mesothelioma. Q J Med 1976; 179: 427-449
• Gazdar AF, Butel JS, Carbone M. SV-40 and Human Tumours : Myth, association or causality?. Nature Reviews Cancer. 2002 ; 2 : 957-964
• Hejmadi R, Ganesan R, Kamal NG. Malignant transformation of a well-differentiated peritoneal papillary mesothelioma. Acta Cytol. 2003;47: 517–8.
• Höllinger P, Gaeng D. Simultaneous bilateral spontaneous pneumothorax in a patient with peritoneal and pleural papillary mesothelioma. Respiration. 1997 ; 64 : 233 – 235
• Lee YK, et al. Therapeutic Strategies for Well-differentiated Papillary Mesothelioma of the Peritoneum. Japannese Journal of Clinical Oncology 2013; 43 (10): 996-1003.
• Legha SS, Muggia FM: Pleural mesothelioma: clinical features and therapeutic implications. Ann Intern Med 1977; 87: 613-621
• Medscape – Treatment and Management Superior Vena Cava Syndrome. Available at http://emedicine.medscape.com/article/460865-treatment. Accessed on 20 October 2014.
• Moore AJ, Parker RJ, Wiggins J. Malignant Mesothelioma. Orphanet Journal of Rare Diseases 2008, 3:34
• Muley T, Dienemann H, Herth FJF, Thomas M, Meister M, Schneider J. Combination of Mesothelin and CEA Significantly Improves the Differentiation between Malignant Pleural Mesothelioma, Benign Asbestos Disease, and Lung Cancer. J Thorac Oncol. 2013;8: 947-951
• Ordonez NG. Role of immunohistochemistry in distinguishing epithelial peritoneal mesotheliomas from peritoneal and ovarian serous carcinoma. Am J Surg Pathol 1998 ; 22 : 1203–1214
• Ratzer ER, Pool JL, Melamed MR: Pleural mesotheliomas. Clinical experiences with thirty seven patients. Am J Roentgenol 1967; 99: 863-880
• Riberio C, Campelos S, Moura CS, Machado JC, Justino A, Parente B. Well-differentiated papillary mesothelioma: clustering in a Portuguese family with a germline BAP1 mutation. Annals of Oncology 2013; 24: 2147–2150.
• Rowell, NP and FV Gleeson. Steroids, radiotherapy, chemotherapy and stents for superior vena caval obstruction in carcinoma of the bronchus: a systemic review. Clinical Oncology 14; 2002. p. 338-351
• Sterman DH, Litzky LA, Albelda SM. “Chapter 88”. Fishman’s Pulmonary Disease and Disorder (4th ed.). McGraw Hill. 2008
• Tumour Pleura Chapter 2. Available at http://www.iarc.fr/en/publications/pdfs-online/pat-gen/bb10/bb10-chap2.pdf. Accessed on 19 October 2014.
• Wan JF, Bezjak A, 2009. Superior Vena Cava Syndrome. Emerg Med Clin N Am 27, pp 243-255
• Washimi K,Yokose T, Amitani Y, Nakamura M, Osanai S, et al. Well-differentiated papillary mesothelioma, possibly giving rise to diffuse malignant mesothelioma: A case report. Pathology International 2013; 63: 220 – 225

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.